FOI release

Freedom of Information request (FOI 22/1164)

Published 17 January 2024

FOI 22/1164

14th December 2022

Dear

Thank you for your communication, dated 2nd December 2022, in which you requested the following information:

‘if the medicinal products Tazocin 4 g/0.5 g and Tazocin 2 g/0.25 g (piperacillin and tazobactam) by Pfizer Limited has a Risk Management Plan in place?

If yes, I would be grateful if you could share the list of safety concerns presented in that RMP or summary RMP. If possible, please let me know if any of the safety concerns has:

  • a specific follow-up questionnaire,
  • additional PV activities or additional risk minimization measures.’

Regarding your request for the Risk Management Plan (RMP), as the Marketing Authorisation application for Tazocin 4 g/0.5 g and Tazocin 2 g/0.25 g (piperacillin and tazobactam) was made prior to the 2012 amendment in pharmacovigilance legislation, which requires an RMP for all new applications, the MHRA does not hold an RMP for this product.

We hope you find this helpful. If you have a query about the information provided, please reply to this email.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: [email protected]

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information

Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner’s Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF Yours sincerely

FOI Team,

Safety and Surveillance